EUVIMEDEUVIMED entdecken
Open Access

GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer

Zihao Zhang, Wenxin Xu, Kuan Yu, Anran Bao, Yifan Cao, Mincheng Yu, Qiang Yu, Yufei Zhao, Liang Gong, Peiyi Xie, Zhenbin Shen, Jing Qin

Cancer Communications · 2026

DOI: 10.34133/cancomm.0054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2026. Verfasst von Zihao Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Resistance, Neoplasm, Tumor-Associated Macrophages, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have substantially improved the treatment of multiple cancers; however, only a small proportion of gastric cancer (GC) patients achieve durable clinical benefit. The underlying tumor-intrinsic mechanisms driving resistance to anti-PD-1 therapy remain poorly understood. This study aimed to identify key regulators of immunotherapy resistance in GC and to elucidate their functional and mechanistic roles.

Methods

Transcriptomic data from anti-PD-1-responsive and anti-PD-1-resistant GC patients were analyzed and integrated with mouse model data and publicly available single-cell RNA sequencing datasets. Functional experiments, including in vitro assays and in vivo tumor models, were performed to validate candidate genes and explore their roles in tumor progression and immunotherapy resistance.

Results

GULP PTB domain-containing engulfment adaptor 1 (GULP1) was identified as a key driver of resistance to anti-PD-1 therapy in GC. Elevated GULP1 expression was associated with poor prognosis and unfavorable clinical responses to PD-1 blockade. GULP1 promoted GC progression and attenuated the therapeutic efficacy of anti-PD-1 treatment. Functionally, GULP1 facilitated the accumulation and metabolic reprogramming of CD36 + programmed death-ligand 1 (PD-L1) + tumor-associated macrophages (TAMs) by shaping a lipid-enriched tumor microenvironment, thereby impairing CD8 + T-cell function. Mechanistically, GULP1 promoted insulin-induced gene 2 (INSIG2) palmitoylation through the recruitment of zinc finger DHHC-type palmitoyltransferase 8 (zDHHC8), resulting in sterol regulatory element-binding protein 1 (SREBP1) nuclear translocation and enhanced de novo fatty acid biosynthesis. Importantly, pharmacological inhibition of Gulp1 with glycyrrhizic acid significantly restored sensitivity to anti-PD-1 therapy in vivo.

Conclusions

Collectively, these findings uncovered a previously unrecognized GULP1–fatty acid–CD36 + PD-L1 + TAM–CD8 + T-cell axis that drove resistance to PD-1 blockade in GC, highlighting GULP1 as a promising therapeutic target and predictive biomarker for immunotherapy responsiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsDrug Resistance, NeoplasmTumor-Associated MacrophagesAdaptor Proteins, Signal TransducingImmune Checkpoint InhibitorsHumansAnimalsMetabolic ReprogrammingMiceProgrammed Cell Death 1 ReceptorCell Line, TumorTumor MicroenvironmentLipid Metabolism

Substanzen

Adaptor Proteins, Signal TransducingProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
  • Gastric Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
  • Department of Hepatobiliary Surgery and Transplantation, Liver Cancer Institute, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
  • Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Z., Xu, W., Yu, K., Bao, A., Cao, Y., Yu, M., Yu, Q., Zhao, Y., Gong, L., Xie, P., Shen, Z., & Qin, J. (2026). GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer. Cancer Communications. https://doi.org/10.34133/cancomm.0054

Vancouver

Zhang Z, Xu W, Yu K, Bao A, Cao Y, Yu M, et al. GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer. Cancer Communications. 2026. doi:10.34133/cancomm.0054

BibTeX
@article{Zhang2026,
  author = {Zhang, Zihao and Xu, Wenxin and Yu, Kuan and Bao, Anran and Cao, Yifan and Yu, Mincheng and Yu, Qiang and Zhao, Yufei and Gong, Liang and Xie, Peiyi and Shen, Zhenbin and Qin, Jing},
  title = {GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer},
  journal = {Cancer Communications},
  year = {2026},
  doi = {10.34133/cancomm.0054}
}
Kostenlos starten →